Long-term excess risk of breast cancer after a single breast density measurement. by Rebolj, M et al.
European Journal of Cancer 117 (2019) 41e47Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.ejcancer .comOriginal ResearchLong-term excess risk of breast cancer after a single
breast density measurementMatejka Rebolj a,b,*, Oleg Blyuss b,d, Kee Seng Chia c,
Stephen W. Duffy b,**a Cancer Prevention Group, School of Cancer & Pharmaceutical Sciences, Faculty of Life Sciences & Medicine,
King’s College London, London SE1 9RT, UK
b Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Barts & The London School of Medicine and
Dentistry, Queen Mary University of London, London EC1M 6BQ, UK
c Saw Swee Hock School of Public Health, National University of Singapore, Singapore
d Department of Paediatrics, Sechenov University, Moscow, RussiaReceived 12 March 2019; received in revised form 2 May 2019; accepted 3 May 2019
Available online 21 June 2019KEYWORDS
Breast cancer;
Breast density;
Excess risk;
Screening;
Mammography* Corresponding author: Cancer Preve
College London, London SE1 9RT, UK
** Corresponding author:
E-mail addresses: matejka.rebolj@kc
https://doi.org/10.1016/j.ejca.2019.05.009
0959-8049/ª 2019 The Authors. Publish
licenses/by/4.0/).Abstract Aim: Breast density is a risk factor for breast cancer. As density changes across a
woman’s life span, we studied for how long a single density measurement taken in (post-)
menopausal women remains informative.
Methods: We used data from Singaporean women who underwent a single mammography
screen at age 50e64 years. For each case with breast cancer diagnosed at screening or in
the subsequent 10 years, whether screen detected or diagnosed following symptoms, two
age-matched controls were selected. We studied the excess risk of breast cancer, calculated
as an odds ratio (OR) with conditional logistic regression and adjusted for body mass index,
associated with 26e50% and with 51e100% density compared with 25% density by time
since screening.
Results: In total, 490 women had breast cancer, of which 361 were diagnosed because of symp-
toms after screening. Women with 51e100% breast density had an excess risk of breast cancer
that did not seem to attenuate with time. In 1e3 years after screening, the OR was 2.22 (95%
confidence interval [CI]: 1.07e4.61); in 4e6 years after screening, the OR was 4.09 (95% CI:
2.21e7.58), and in 7e10 years after screening, the OR was 5.35 (95% CI: 2.57e11.15). Excess
risk with a stable OR of about 2 was also observed for women with 26e50% breast density.
These patterns were robust when the analyses were limited to post-menopausal women, non-
users of hormonal replacement therapy and after stratification by age at density measurement.ntion Group, School of Cancer & Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King’s
.
l.ac.uk (M. Rebolj), s.w.duffy@qmul.ac.uk (S.W. Duffy).
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M. Rebolj et al. / European Journal of Cancer 117 (2019) 41e4742Conclusion: A single breast density measurement identifies women with an excess risk of breast
cancer during at least the subsequent 10 years.
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About 40% of women have heterogeneously or
extremely dense breasts (as defined by Breast Imaging-
Reporting and Data System [BI-RADS], categories 3e4;
this typically involves dense tissue in 50% of the
breast), of which ca. 5e10% have extremely dense
breasts (BI-RADS 4; typically 75% dense tissue) [1,2].
In an extensive meta-analysis, adjusted for age, the
relative risk (RR) of breast cancer in women with
50e74% dense breast tissue approached three (RR: 2.92,
95% CI: 2.49e3.42) compared with women whose
breasts are composed of >95% fatty tissue, while the
relative risk in women with 75% dense tissue was
estimated to be about 4e5 (RR: 4.64, 95% CI:
3.64e5.91) [3].
Dense breast tissue is mainly fibroglandular and ap-
pears white instead of translucent on a mammogram,
and this whiteness can mask prevalent cancers [4]. At
least 29% (95% CI: 27e31) of cancers in dense breasts
are not detectable by mammography [5]. In a US study,
taking into account symptomatic cancers diagnosed 2
years after a negative screening mammogram, the
mammographic sensitivity was 72% overall, but only
30% in women with extremely dense and 60% in women
with heterogeneously dense breasts, whereas, it was 80%
in women with predominantly fatty breasts [6].
Breast density changes across a woman’s life course
[7,8]. Most prominently, it decreases with age and,
independently, with menopausal transition, as fibro-
glandular tissue is replaced with fat [9,10]. While density
is associated with several non-modifiable factors such as
genetics and race [11,12], various modifiable factors also
play a role such as women’s lifestyles [7,11,13e17] and
use of medication, such as hormonal replacement ther-
apy (HRT), which increases density, or tamoxifen,
which reduces it [7,17e22].
Given this dynamic in breast density, we investigated
for how long a single density measurement taken at 50
years of age remains predictive of the excess risk of
breast cancer.
2. Material and methods
2.1. Study population
The study population was described in detail previously
[23e28]. Briefly, all women permanently residing in
Singapore in 1994 aged 50e64 years (NZ 166,600) wererandomised to either a single round of breast screening
with mammography (N Z 69,473) or standard care;
exclusion criteria were a recent mammogram or breast
biopsy, pregnancy, or history of cancer other than non-
melanoma cancer. One thousand women invited to
participate in the trial were aged 45e49 and 65e69
years. Between October 1994 and February 1997, 42%
of the invited women underwent a two-view, film-screen,
mammographic examination that was evaluated by two
radiologists. Women were managed according to the
most suspicious of the two readings and could be either
discharged, recalled for further films or recalled for joint
assessment. Women’s sociodemographic characteristics
were determined through a questionnaire administered
at screening. Mammography screening was infrequent
before the trial; after it had closed, mammography was
only offered within a screening programme from 2002
onward, but the coverage rate was below 40% [29]. The
trial was approved by the National University of
Singapore Institutional Review Board.
Information on all breast cancers (including invasive
and ductal carcinoma in situ cases and both screen-
detected cases as well as those diagnosed following
symptoms) was retrieved until 2005 from pathology re-
cords of the two participating screening hospitals or
through linkage with the national cancer registry. Each
screened woman with a breast cancer diagnosis
(N Z 491) was matched on age and ethnicity with two
women (N Z 982) with a mammogram who had not
developed breast cancer; the same selection of cases and
controls was studied previously by Wong et al. [25].
2.2. Breast density measurements
Density was estimated retrospectively using screening
mammograms from both the cases and their matched
controls. Although this work was undertaken after the
case-control status had become known, the final disease
status was not revealed during the density scoring pro-
cess. Percent breast density was estimated in the
contralateral breast using the quantitative Cumulus
interactive threshold method [30]. This information was
not used for clinical management.
2.3. Statistical analysis
The differences in the distributions of dichotomised
sociodemographic risk factors (at most primary level of
education, age at menarche 14 years, premenopausal
Table 1
Description of the studied women at the time of screening, by mode of cancer detection.
N All cancers Screen-detected cancers Symptomatic cancers
Cases Controls P Cases Controls P Cases Controls P
491 982 129 258 362 724
Age, mean (SD) 57.4 (4.0) 57.3 (4.1) NR 57.9 (4.1) 57.8 (4.5) NR 57.2 (4.0) 57.2 (4.0) NR
Age, median (IQR) 56.6 (54.3e60.5) 56.6 (54.1e60.6) NR 57.4 (54.7e61.2) 57.2 (53.9e61.4) NR 56.3 (54.2e60.2) 56.5 (54.2e60.3) NR
BMI, median (IQR) 24.7 (22.4e27.2) 23.9 (21.5e26.7) <0.01 24.8 (21.8e26.7) 23.8 (21.4e26.6) 0.48 24.6 (22.6e27.4) 24.0 (21.6e26.8) <0.01
% Chinese 422 (86%) 844 (86%) NR 112 (87%) 224 (87%) NR 310 (86%) 620 (86%) NR
No or primary
education
322 (68%) 753 (77%) <0.01 92 (71%) 204 (79%) 0.09 240 (66%) 549 (76%) <0.01
Age at menarche
£14 years
295 (60%) 514 (52%) <0.01 75 (58%) 125 (48%) 0.07 220 (61%) 389 (54%) 0.02
Premenopausal 71 (14%) 109 (11%) 0.03 18 (14%) 37 (14%) 0.90 53 (15%) 72 (10%) 0.01
No live births 70 (14%) 95 (10%) <0.01 23 (18%) 28 (11%) 0.07 47 (13%) 67 (9%) 0.06
Ever used HRT 90 (19%) 130 (13%) <0.01 18 (14%) 35 (14%) 0.92 72 (20%) 95 (13%) <0.01
BMI, body mass index; HRT, hormonal replacement therapy; NR, not relevant; this was a matching variable, so inference is not applicable; IQR,
interquartile range; SD, standard deviation.
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and their matched controls were assessed with condi-
tional logistic regression. For the continuous measures
of body mass index (BMI) and percent density, the
differences (calculated as: [BMI control1 þ BMI con-
trol2 - 2  BMI case]/2 and equivalent for percent
density) were assessed using the t test. A Shapiro-Wilk
test for non-normality was not significant: P Z 0.42 for
BMI and P Z 0.77 for percent density. The differences
between cases and controls in the categorical distribu-
tions of breast density (classified as 0e10%, 11e25%,
26e50%, 51e75% and 76e100%) were evaluated using
the c2 statistic.
The risk of breast cancer associated with breast
density was calculated with conditional logistic regres-
sion. When the risk was calculated by year since
screening, percent density was categorised as 25%,
26e50% and 51% to avoid cells with small numbers.
To keep the models simple, they were adjusted for BMI
only, while age and ethnicity were controlled for in the
matching. In an earlier analysis of the same data set [25],
further adjustment for age at menarche, number of de-
liveries, age at first birth, use of oral contraceptives,
HRT use and menopausal status did not substantially
change the BMI-adjusted overall odds ratios (ORs) for
the association of density with breast cancer risk.Table 2
Description of breast density patterns among the studied women, by mode
N All cancers Screen-
Cases Controls P Cases
491 982 129
0e10% 33 (7%) 117 (12%) <0.01 3 (2%)
11e25% 76 (15%) 282 (29%) 19 (15%
26e50% 215 (44%) 391 (40%) 58 (45%
51e75% 151 (31%) 171 (17%) 42 (33%
76e100% 16 (3%) 21 (2%) 7 (5%)
Mean percent (SD) 42 (20) 33 (19) <0.01 46 (20)
SD, standard deviation.All analyses were undertaken with R Studio, version
1.1.419.3. Results
Of the 491 cancers, 129 (26%) were detected at screening
within the trial, and 362 (74%) were diagnosed outside of
the trial, most likely as a result of seeking medical advice
for symptoms. Among the 491 cases, three (1%) were
younger than 50 years at screening, 157 (32%) were aged
50e54, 196 (40%) were aged 55e59, 115 (23%) were aged
60e64 and 20 (4%) were aged 65 years. Cases were sta-
tistically significantly less likely to have at most primary
education than controls; theywere alsomore likely to have
a higher BMI, be younger at menarche, to have ever used
HRT and were slightly more likely to be nulliparous and
premenopausal (Table 1). These relationships were
roughly preserved after stratification by mode of detec-
tion, although the numbers were smaller for women with
screen-detected cancers, and the differences did not reach
statistical significance.
Cases had significantly denser breasts than controls,
with 22% of cases and 41% of controls having 0e25%
density and 34% of cases and 19% of controls having
51e100% density (Table 2). Cases had on average 42%of cancer detection.
detected cancers Symptomatic cancers
Controls P Cases Controls P
258 362 724
33 (13%) <0.01 30 (8%) 84 (12%) <0.01
) 76 (29%) 57 (16%) 206 (28%)
) 98 (38%) 157 (43%) 293 (40%)
) 45 (17%) 109 (30%) 126 (17%)
6 (2%) 9 (2%) 15 (2%)
33 (20) <0.01 41 (20) 34 (19) <0.01
Table 3
Risk of breast cancer (expressed as odds ratios) by breast density and mode of detection, adjusted for BMI.
All cancers Screen-detected cancers Symptomatic cancers
Cases/controls 490/980 129/258 361/722
Breast density
0e10% 1 (ref) 1 (ref) 1 (ref)
11e25% 1.14 (0.70e1.85) 4.32 (1.11e16.79) 0.86 (0.51e1.47)
26e50% 2.67 (1.69e1.85) 11.53 (3.00e44.33) 1.93 (1.18e3.15)
51e75% 4.66 (2.83e7.65) 22.24 (5.36e92.27) 3.32 (1.93e5.69)
76e100% 5.74 (2.54e12.95) 33.74 (5.70e199.80) 3.54 (1.32e9.52)
Per 1 percentage point increase 1.03 (1.02e1.04) 1.04 (1.03e1.06) 1.03 (1.02e1.04)
BMI, body mass index.
Three women (1 case, 2 controls) had an unknown BMI, and these trios were excluded from the analysis.
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whereas in controls, this was 33% (P < 0.01). Breast
density was correlated with age. Cases aged 50e54 years
had a median percent density of 48, those aged 55e59
years had 40 and those aged 60e64 years had 35.
Among controls, this was 38, 31 and 23, respectively
(data not tabulated).
As expected, the risk of cancer detected at screening
or in the subsequent 10 years increased with percentage
of breast density, with about a five-fold increase in the
risk in women with 51% density compared with
women with 10% density (Table 3; OR for 51e75%
density: 4.66, 95% CI: 2.83e7.65 and OR for 76e100%
density: 5.74, 95% CI: 2.54e12.95). Each percentage
point increase in breast density was estimated to increase
the risk of cancer by 3% (95% CI: 2e4). While the risk
was substantially more pronounced for screen-detected
cancers, it remained statistically significantly increased
for symptomatic cancers.
Only 19 (5%) of the 361 symptomatic cancers in our
study were diagnosed within the first year after
screening, and the effect of breast density was not sta-
tistically significant (Table 4). Four to six years after
screening when 150 (42%) symptomatic breast cancers
were diagnosed, women with 26e50% density had an
OR of breast cancer of 2.17 (95% CI: 1.27e3.71)
compared with those with 25% density, and those with
51e100% had an OR of 4.09 (95% CI: 2.21e7.58). One
hundred sixteen (32%) symptomatic cancers were diag-
nosed 7 or more years after screening, when women with
26e50% density still had an increased risk of breastTable 4
Risk of symptomatic breast cancer (expressed as odds ratios) by breast de
Total <1 ye
Cases/controls 361/722 19/38
Breast density
0e25% 1 (ref) 1 (ref
26e50% 2.13 (1.53e2.97) 3.73 (
51e100% 3.70 (2.53e5.42) 2.87 (
Per 1 percentage point increase in breast density 1.03 (1.02e1.04) 1.01 (
BMI, body mass index.
Three women (1 case, 2 controls) had an unknown BMI, and these trios wcancer with an OR of 2.46 (95% CI: 1.32e4.58), as did
women with 51% density, OR 5.35 (95% CI:
2.57e11.15). A test for interaction between breast den-
sity and time since screening was not significant, and
consequently, an interaction term was not included in
the models.
The same patterns were observed when the analysis
was restricted to 270 (75%) out of 362 symptomatic
cancer case-control trios in which all three women were
post-menopausal; when restricted to 227 (63%) of trios
in which none of the women previously took HRT;
when the analysis included only 310 (86%) trios that
comprised of women of Chinese origin and when strat-
ified by age group (<56 years versus 56, the sample’s
median; data not reported).
4. Discussion
A single mammographic measurement showing high
breast density around or after menopause has long-term
informational value for a woman’s excess risk of
developing breast cancer. In our predominantly post-
menopausal sample of women undergoing a single
mammography screen at age 50e64 years, the overall
relative risk was about four in those with dense tissue
covering at least half of their mammogram area
compared with those with dense tissue in less than a
quarter of their mammogram. This relationship was
robust when analyses were stratified by age, post-
menopausal status and use of HRT. This risk remained
significantly elevated for at least 10 years and did notnsity and time since screening, adjusted for BMI.
ar 1e3 years 4e6 years 7e10 years
76/152 150/299 116/233
) 1 (ref) 1 (ref) 1 (ref)
0.89e15.73) 1.67 (0.87e3.22) 2.17 (1.27e3.71) 2.46 (1.32e4.58)
0.64e12.84) 2.22 (1.07e4.61) 4.09 (2.21e7.58) 5.35 (2.57e11.15)
0.99e1.04) 1.02 (1.01e1.04) 1.03 (1.02e1.04) 1.03 (1.02e1.04)
ere excluded from the analysis.
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observation period.
To detect cancers in women with dense breasts
missed by mammography, some countries are now of-
fering complementary ultrasound screening [31]. Our
results suggest that women with high breast density at
age 50 years could be scheduled to undergo supple-
mentary ultrasound screening and remain being
considered for the dual screening modality for the
following 10 years. Nevertheless, additional studies
would need to confirm whether this approach could be
cost-effective and feasible given the available health-
care capacities.
Our study was undertaken in a population of Asian
descent with a somewhat higher average percent breast
density than in many Western populations, although the
proportion of women with 50% density was not
exceptionally high [7,10,32]. Women in the trial under-
went a single mammographic screen, although we could
not ascertain whether any of them obtained additional
mammography elsewhere, e.g. through the national
screening programme rolled out in 2002. The Singapore
cancer registry is highly complete [33], and emigration
from the country was not high at least during the 1990’s
[34], leading to limited, if any, misclassification of case-
control status in our study.
The observation that the ORs were substantially
higher for screen-detected cancers than for symptomatic
cancers may be somewhat surprising. These ORs are
driven not by very high rates of cancer detection in
dense breasts but very low rates in non-dense breasts
(Table 2). They are partly dependent on the baseline
category. In our analysis, this was very non-dense
(10%), a relatively rare group in this population,
which we suspect is confounded with a number of
important but unobserved risk factors. If we had chosen
25% density as our baseline category, the ORs would
have been of the order of 1.5e2 times higher for screen-
detected, rather than 10 times higher as in Table 3. The
results remain surprising, although not completely un-
precedented. For example, Nickson et al. [35] found a
greater risk gradient with density for large screen-
detected cancers than for interval cancers.
Our results are broadly consistent with those from
earlier European and Northern American studies. Byrne
et al. [36] collected data from women who underwent
screening in the United States in the 1970’s, and those
with 75% breast density (as compared with those with
0% density) retained about a four-fold excess risk in 5 or
more years after screening (OR: 3.56, 95% CI: 1.8e7.0,
in 5e9.9 years and 4.47, 95% CI: 2.1e9.6, in 10e16
years). From Canada, Boyd et al. [32] reported an OR of
5.5 (95% CI: 2.7e11.2) in more than 4 years after
screening for 75% versus <10% density. In Sweden,
Chiu et al. [37] showed that the cumulative incidence of
breast cancer remained significantly increased over a 25-
year period for women with dense breast patternscompared with women with non-dense breast patterns.
An overall hazard ratio was 1.57 (95% CI: 1.23e2.01),
and the differences between the two groups did not
appear to diminish over time. Nevertheless, two other
US studies showed some attenuation of the excess risk
with time since density measurement, for example
Thomas et al. [38] reported an OR of 3.4 (95% CI:
1.9e6.3) in 3e5 years and 2.9 (95% CI: 1.4e6.3) in 6
years for 70.3% versus 26.7% density, while
Yaghjyan et al. [39] reported an OR of 3.91 (95% CI:
2.22e6.88) in 5e9 years for 50% versus <10% density,
but a lower and not statistically increased OR of 1.22,
95% CI: 0.42e3.57, beyond 9 years.
The fact that a single density measure in post-
menopausal women retains its informational value in
the long term may be related to a gradual stabilisation of
the decline in breast density after menopause. McCor-
mack et al. [10] estimated that breast density declines by
1.4% (95% CI: 1.2e1.6) per year around age 50 years
and by 0.7% (95% CI: 0.6e0.9) around age 57 years, but
that the decline is almost 0% per year around age 65
years. Using cross-sectional data from 22 countries,
Burton et al. [40] found that mean percent breast density
declined from 27.4% at 45e49 years of age to 22.5% at
50e54 and 18.7% at 55e59 years and then stabilised
around 17% from age 60 years onward. Very similar
patterns were observed in multiple other studies [7,18].
This stabilisation of breast density after menopausal
transition leads to a high degree of ‘tracking’, whereby
women whose breast density ranked high on the initial
mammograms still rank high on later mammograms
despite absolute changes from the earlier to the later
time point [10].
Another reason for density measurements retaining
their association with breast cancer in the long term may
be the relative inelasticity of breast cancer risk to a
declining breast density. Women with initially high
density do not experience a substantially decreased risk
even in the event that their breast density decreases at a
later age [41,42]. Consequently, sequential measure-
ments of breast density improve the prediction of breast
cancer risk only marginally and if so, predominantly in
women with additional risk factors [42].
For a woman’s excess risk of breast cancer to
diminish to a meaningful degree, the decrease in density
may need to be substantially larger than the sponta-
neous changes brought about by ageing and menopause,
estimated at about 1% per year [7,9,10,41]. This was
demonstrated in the International Breast Cancer Inter-
vention Study where cancer-free high-risk women aged
30e70 years were randomly assigned to either tamoxifen
or placebo for 5 years [22]. Among those who used
tamoxifen, 48% experienced a reduction of breast den-
sity of 10% points in on average 1e1.5 years after the
start of the trial. This sudden large change in density
decreased the risk of cancer by 63% (95% CI: 31e80)
compared with all women on placebo.
M. Rebolj et al. / European Journal of Cancer 117 (2019) 41e47465. Conclusion
A single high breast density measurement identifies
(post-menopausal) women who continue to have an
excess risk of breast cancer for at least 10 years.Conflict of interest statement
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